Caption Management, LLC Allakos Inc. Transaction History

Caption Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.72 - $3.18 $24,080 - $44,520	14,000 New	14,000 $38,000
Q3 2021 Nov 12, 2021	SELL	$76.53 - $110.43 $1.04 Million - $1.49 Million	-13,536 Reduced 46.3%	15,700 $1.66 Million
Q1 2021 May 17, 2021	BUY	$109.73 - $153.66 $2.3 Million - $3.22 Million	20,936 Added 252.24%	29,236 $3.36 Million
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $660,514 - $1.27 Million	8,300 New	8,300 $1.16 Million
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $164,613 - $345,543	-3,700 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$66.49 - $137.73 $2.12 Million - $4.39 Million	-31,900 Reduced 89.61%	3,700 $353,000
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $1.1 Million - $3.19 Million	35,600 New	35,600 $2.8 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $74.6M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.